Hologic Inc

Hologic is a U.S.-based medical technology company focused on women’s health, combining diagnostics, breast imaging, gynecologic surgery and bone health products. It develops, manufactures, sells and services premium systems and consumables used for early detection, diagnosis and treatment across hospitals, laboratories and physician practices.

20,1 %

51,6 %

13,8 %

+1,7 %

3.75

3.06

— Hologic Inc
%
Diagnostics40% Molecular diagnostic instruments, assays and related consumables used by clinical laboratories and healthcare providers.
Breast Health35% Breast imaging, biopsy, localization and related products used for screening and diagnosis.
GYN Surgical15% Gynecologic surgical systems and disposable products used in minimally invasive procedures.
Skeletal Health10% Bone density and orthopedic imaging systems, including DXA and mini C-arm products.

Hologic sells to clinical laboratories, hospitals, healthcare systems and physicians, with distinct buying centers...

  • Clinical laboratoriesprimary

    Buy diagnostic instruments, assays and consumables for infectious disease and other testing workflows.

  • Hospitals and integrated delivery networksprimary

    Buy breast imaging, biopsy and surgical systems through capital and purchasing contracts.

  • Physician practices and specialty clinicssecondary

    Buy GYN surgical and bone health products for office-based and ambulatory procedures.

  • Large purchasing organizationssecondary

    Managed care organizations, IDNs and government facilities negotiate access and pricing.

  • International distributorssecondary

    Sell and service products in markets where Hologic uses indirect channels.

Hologic is headquartered in the United States and generates sales through direct teams and distributors across North...

  • United States is the core market for sales, service and clinical adoption
  • Western Europe is a major direct-sales region for imaging and diagnostics
  • China, Japan, Australia and South Korea are key international growth markets
  • Canada is served through direct sales and distributor relationships
  • Indirect channels matter where Hologic lacks full direct coverage

Hologic’s strategy centers on women’s health across the care continuum, using clinical evidence, FDA labeling and...

01
Defend and grow women’s health franchisesmedium-term

Clinical evidence and product breadth help sustain pricing and customer loyalty in competitive markets.

02
Strengthen direct sales and service executionshort-term

Direct customer relationships improve adoption, service quality and recurring revenue from the installed base.

03
Optimize portfolio and capital structureshort-term

Acquisitions, divestiture-like product exits and the pending take-private transaction affect long-term flexibility.

Hologic faces intense competition from larger medtech and diagnostics companies, which can pressure pricing,...

high

Competitive pressure across diagnostics, imaging and surgery

Larger rivals may offer broader portfolios, stronger brands or lower prices, reducing Hologic's pricing power.

Scope
Average selling prices, procedure volumes and market share
Materiality
high
high

Merger closing uncertainty

The Blackstone/TPG transaction depends on stockholder, regulatory and other closing conditions.

Scope
Stock price, strategic focus and transaction-related costs
Materiality
high
high

Cybersecurity and IT failures

Connected medical products and data systems can be targeted by ransomware, phishing and other attacks.

Scope
Operations, customer trust, regulatory exposure and remediation costs
Materiality
high
medium

Diagnostics customer concentration

A limited number of customers account for a meaningful share of Diagnostics revenue.

Scope
Segment revenue and profitability
Materiality
medium
medium

Distributor dependence in international markets

Loss or underperformance of distributors can reduce sales and service reach in serviced territories.

Scope
International revenue and installed-base support
Materiality
medium
Revenue recognition for multiple-element arrangements
Quarterly revenue timing and deferred revenue balances
Inventory reserves and excess/obsolete stock
Gross margin and operating income
Goodwill and intangible asset impairment
Potential non-cash impairment charges
Contingent consideration and acquisition accounting
Earnings volatility and balance-sheet liabilities
Tax valuation allowances and uncertain tax positions
Tax expense and net income

: 28/04/2026